|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | +3.34% |
|
-10.05% | -61.32% |
| Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
| Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Revance Therapeutics, Inc. provided revenue guidance for the year 2024. The company expects 2024 total product revenue, which includes sales of DAXXIFY and the RHA Collection, to be at least $280 million.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.32% | 354M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
REVANCE THERAPEUTICS, INC. 
